Search research articles
Contact Us
Filters
Showing results (11-20 of 88) with videos related to
Page
of 9
Sort By:
Expert Review of Vaccines
|
August 26, 2024
Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells
Massimo Fantini, Kwong Y Tsang, Philip M Arlen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2007
Cancer vaccines: moving beyond current paradigms
Jeffrey Schlom, Philip M Arlen, James L Gulley
Seminars in Oncology
|
December 13, 2005
Pox viral vaccine approaches
Philip M Arlen, Howard L Kaufman, Robert S DiPaola
Vaccine
|
June 19, 2007
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
James L Gulley, Ravi A Madan, Philip M Arlen
Expert Opinion on Biological Therapy
|
March 22, 2007
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Ravi A Madan, Philip M Arlen, James L Gulley
Hematology/Oncology Clinics of North America
|
July 25, 2006
Immunotherapy for prostate cancer: what's the future?
Philip M Arlen, William L Dahut, James L Gulley
The Oncologist
|
May 25, 2006
Therapeutic vaccines for prostate cancer
Christopher P Tarassoff, Philip M Arlen, James L Gulley
Expert Review of Vaccines
|
April 13, 2006
PSA-based vaccines for the treatment of prostate cancer
Ravi A Madan, James L Gulley, Philip M Arlen
Clinical Genitourinary Cancer
|
October 25, 2007
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases
James L Gulley, Shenhong Wu, Philip M Arlen, et al.
Future Oncology (London, England)
|
March 17, 2009
Promising novel immunotherapies and combinations for prostate cancer
Philip M Arlen, Mahsa Mohebtash, Ravi A Madan, et al.
Page
of 9
Search research articles
Search
Showing results (11-20 of 88) with videos related to
Sort By:
Page
of 9
Expert Review of Vaccines
|
August 26, 2024
Generation of the therapeutic monoclonal antibody NEO-201, derived from a cancer vaccine, which targets human malignancies and immune suppressor cells
Massimo Fantini, Kwong Y Tsang, Philip M Arlen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 4, 2007
Cancer vaccines: moving beyond current paradigms
Jeffrey Schlom, Philip M Arlen, James L Gulley
Seminars in Oncology
|
December 13, 2005
Pox viral vaccine approaches
Philip M Arlen, Howard L Kaufman, Robert S DiPaola
Vaccine
|
June 19, 2007
Enhancing efficacy of therapeutic vaccinations by combination with other modalities
James L Gulley, Ravi A Madan, Philip M Arlen
Expert Opinion on Biological Therapy
|
March 22, 2007
PANVAC-VF: poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma
Ravi A Madan, Philip M Arlen, James L Gulley
Hematology/Oncology Clinics of North America
|
July 25, 2006
Immunotherapy for prostate cancer: what's the future?
Philip M Arlen, William L Dahut, James L Gulley
The Oncologist
|
May 25, 2006
Therapeutic vaccines for prostate cancer
Christopher P Tarassoff, Philip M Arlen, James L Gulley
Expert Review of Vaccines
|
April 13, 2006
PSA-based vaccines for the treatment of prostate cancer
Ravi A Madan, James L Gulley, Philip M Arlen
Clinical Genitourinary Cancer
|
October 25, 2007
Persistent hypocalcemia induced by zoledronic acid in a patient with androgen-independent prostate cancer and extensive bone metastases
James L Gulley, Shenhong Wu, Philip M Arlen, et al.
Future Oncology (London, England)
|
March 17, 2009
Promising novel immunotherapies and combinations for prostate cancer
Philip M Arlen, Mahsa Mohebtash, Ravi A Madan, et al.
Page
of 9